Literature DB >> 2363738

Depletion of high-energy phosphates in the central nervous system of patients with systemic lupus erythematosus, as determined by phosphorus-31 nuclear magnetic resonance spectroscopy.

R H Griffey1, M S Brown, A D Bankhurst, R R Sibbitt, W L Sibbitt.   

Abstract

Systemic lupus erythematosus (SLE) can produce profound disturbances in the central nervous system, characterized by encephalopathy, focal neurologic deficits, cerebral infarction, psychosis, and seizures. We used 31P nuclear magnetic resonance (NMR) spectroscopy to determine the in vivo levels of high-energy phosphates in the central nervous system of 10 patients with SLE and 10 age-matched normal controls. 31P NMR spectroscopy was performed on a 1.5-Tesla unit equipped with a dual-tuned 1H-31P surface coil and a software-directed DRESS (depth resolved surface coil spectroscopy) pulse sequence. This procedure detected ADP, ATP, sugar phosphates, phosphocreatine (PCr), inorganic phosphate, phosphomonoesters, and phosphodiesters in the brain tissue of all study subjects. Levels of ATP in the deep white matter of 10 SLE patients were significantly decreased compared with the levels in 10 normal controls, as quantitated by the ratio of ATP:ATP + ADP (mean +/- SD 0.81 +/- 0.11 versus 0.91 +/- 0.05; P less than 0.02). In a subgroup of 4 patients, PCr levels were decreased to a greater extent than the ATP levels. NMR spectroscopic alterations were not related to obvious anatomic lesions, as determined by standard cranial proton magnetic resonance imaging. In 4 SLE patients with markedly abnormal 31P NMR spectra, treatment with prednisone (80 mg/day) normalized the levels of ATP and PCr. Restoration of a normal 31P profile was accompanied by an obvious improvement in the patients' mental status and clinical symptoms. 31P NMR spectroscopy is a powerful new technique for monitoring high-energy phosphate metabolism, and may be particularly useful for characterizing central nervous system disease in patients with neuropsychiatric SLE.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2363738     DOI: 10.1002/art.1780330609

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  6 in total

1.  Abnormal brain diffusivity in patients with neuropsychiatric systemic lupus erythematosus.

Authors:  Gerlof P Th Bosma; Tom W J Huizinga; Simon P Mooijaart; Mark A Van Buchem
Journal:  AJNR Am J Neuroradiol       Date:  2003-05       Impact factor: 3.825

Review 2.  DNA methylation in systemic lupus erythematosus.

Authors:  Christian M Hedrich; Katrin Mäbert; Thomas Rauen; George C Tsokos
Journal:  Epigenomics       Date:  2016-11-25       Impact factor: 4.778

3.  Behavioral heterogeneity in an animal model of neuropsychiatric lupus.

Authors:  Boris Sakic; Steven E Hanna; Jason M Millward
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

4.  Abnormalities of magnetic resonance imaging of the central nervous system in patients with systemic lupus erythematosus correlate with disease severity.

Authors:  A Cauli; C Montaldo; M T Peltz; P Nurchis; G Sanna; P Garau; R Pala; G Passiu; A Mathieu
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

Review 5.  What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectroscopy?

Authors:  J Vion-Dury; D J Meyerhoff; P J Cozzone; M W Weiner
Journal:  J Neurol       Date:  1994-05       Impact factor: 4.849

Review 6.  Metabolic control of the epigenome in systemic Lupus erythematosus.

Authors:  Zachary Oaks; Andras Perl
Journal:  Autoimmunity       Date:  2013-10-16       Impact factor: 2.815

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.